Source before summary
We favor primary records and established reference sources, then state what those sources do and do not show. General background on multiple sclerosis as a topic is not a substitute for individualized medical guidance.
About the resource / 01
About
Myelin Forge is an independent resource on ibogaine research and multiple sclerosis.
Built for people affected by MS, caregivers, and curious professionals seeking careful context on experimental ibogaine research.
Why this exists / 02
Myelin Forge examines limited, early evidence with clear attention to uncertainty, safety, and research quality.
The resource exists to help readers distinguish laboratory signals and case reports from proven care. Its main research context is designed to make that distinction visible rather than smoothing it over.
Scope / 03
What we cover
Myelin Forge organizes information around evidence context, safety questions, and the limits of what can responsibly be concluded. The way the resource is structured is intended to make the scope and boundaries easy to see.
We point readers toward relevant background without presenting a directory of providers or a treatment pathway. For broad context around treatment language, the discussion at what an ibogaine treatment means can help clarify why careful definitions matter.
Working standards / 04
Editorial principles
Short commitments that guide how information is selected, described, and framed.
- 01 / Scientific restraint We separate preliminary observations from conclusions that would require stronger evidence.
- 02 / Safety first Potential harms, uncertainty, and limits are not afterthoughts; they are part of the context.
- 03 / Plain language Technical material is organized for readers who need clarity without false simplification.
- 04 / Evidence context We distinguish registries, published literature, official sources, and anecdotal material by what each can support.
Method / 05
Our editorial approach
Information is sourced and checked against registries, scientific literature, and official materials where they are relevant. Trial records are useful for understanding what is being formally studied, including through the ClinicalTrials.gov registry, but registration alone does not establish effectiveness or safety.
Keep categories separate
Questions about cognition, neuroplasticity, or other conditions are not interchangeable. Readers exploring adjacent material can compare the framing on ibogaine and cognition and neuroplasticity discussions without treating them as evidence for a different question.
Name conflicts and uncertainty
We do not turn early signals into recommendations. Accounts related to ibogaine and ALS or trauma-focused ibogaine material are presented as separate contexts, each with its own limits.
Boundaries / 06
Independent by design
Myelin Forge is not a clinic, medical provider, licensed treatment center, or legal authority. It does not provide medical or legal advice. Readers encountering claims about settings, access, or care should keep independent information separate from provider marketing, including material about a best ibogaine treatment clinic, ibogaine access in the United States, or ibogaine in rugby conversations.
For people who want a cautious route through this material, the resource is organized to support questions, not to replace qualified care or personal decision-making.
“Clear information is not a promise of an outcome. It is a way to see the difference between a possibility, a claim, and evidence.” Myelin Forge editorial principle